Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1528 • ACR Convergence 2025
Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
Esteban C. Garza-Gonzalez¹, Fernanda M. Garcia-Garcia², Oscar Azael Garza-Flores³, Rebeca L. Polina-Lugo⁴, Leslie Y. Lopez-Cantú², Jose R Azpiri-Lopez⁵, Iris J. Colunga-Pedraza², Jesus Alberto Cardenas-de la Garza⁶, Dionicio A. Galarza-Delgado² and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…
Abstract Number: 1504 • ACR Convergence 2025
High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Richard Oppong¹, Joanne Nititham², Ashira Blazer³, Manuel Ugarte-Gil⁴, Jinoos Yazdany⁵, Maria Dall'Era⁶, Alexander Bick⁷, Lindsey Criswell² and Cristina Lanata⁸, ¹National Institutes of Health, Bethesda, MD, ²NIH/NHGRI, Bethesda, MD, ³University of Maryland Baltimore, Baltimore, Maryland, ⁴Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁵UCSF, San Francisco, CA, ⁶Division of Rheumatology, University of California, San Francisco, CA, ⁷Vanderbilt University, Nashville, TN, ⁸NIH/NHGRI, Bethesda
Background/Purpose: Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of somatic mutations in hematopoietic stem cells that lead to the expansion of…
Abstract Number: 1487 • ACR Convergence 2025
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
Jennifer Rogers¹, Amanda Eudy², Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Christie Clipper⁶, Ralph Snyderman⁷, Anna Batsakes⁶, Leigh Saner⁶, Dana Burshell³, Mithu Maheswaranathan⁴, Lisa Criscione-Schreiber⁴, Rebecca Sadun⁸, Nathaniel Harris⁵, Kai Sun⁸, Kelsey Dunn⁶, Jenny Herndon⁶, Vonne Jacobs⁶ and Megan Clowse⁹, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Duke University, Durham, NC, ⁹Duke University, Chapel Hill, NC
Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…
Abstract Number: 1470 • ACR Convergence 2025
Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
Nidaa Bukhari¹, Ali Rizvi¹, Jian sun¹, Zerai Manna², Paul Schaughency³, Suraj Rajasimhan⁴ and Sarfaraz Hasni¹, ¹National Institutes of Health, BETHESDA, MD, ²NIH, Bethesda, MD, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Columbia, MD
Background/Purpose: Nonadherence to medication is a significant confounder in assessing treatment efficacy for systemic lupus erythematosus (SLE), with rates reported up to 75% depending on…
Abstract Number: 1281 • ACR Convergence 2025
Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
Alicia Tran¹, Indrani Das², Zhaoyu Ding³, Daniela Dominguez⁴, Sefi Kronenberg⁵, Lawrence Ng⁶, Alene Toulany¹, Gwyneth Zai⁷, Deborah Levy¹, Andrea Knight⁸ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷Centre for Addiction & Mental Health, Toronto, ON, Canada, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) face higher risks of depression and anxiety compared to healthy peers. In 2022, standardized mental health (MH)…
Abstract Number: 1087 • ACR Convergence 2025
Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Zoe Reed¹, Catriona Wagner², Xana Howard¹, Alexandre Cammarata-Mouchtouris¹, Study Team ALE⁰⁶ Clinical¹, Wade DeJager³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with considerable clinical and molecular heterogeneity. Significant disparities exist in SLE, with minority populations experiencing…
Abstract Number: 0952 • ACR Convergence 2025
Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus
Rachael Werner¹, Jena Wirth¹, Gary Gilkeson¹ and Melissa Cunningham², ¹Medical University of South Carolina, Charleston, SC, ²Medical University of SC, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects women, underscoring the critical role of sex chromosomes and sex hormones—particularly estrogen—in…
Abstract Number: 0915 • ACR Convergence 2025
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Yuhao Qin¹, Huan Wang¹, Han Gao¹, Chongqi Zhang¹, Chengpan Wang¹, yanru fan¹, wei ye¹, yuan lin¹, Lu Su², Wenming Ren¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), ²Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China
Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
Abstract Number: 0657 • ACR Convergence 2025
Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
FNU Ruchi¹, Ioana Coman¹, Bryan Blaker¹, Lucero Blaker¹, Joy Park², Jorge Cabezas¹, Dilip Rao¹, +Xiaojing Wang¹, Aparna Godavarthy¹, Marlene Marte Furment³, Sandy Nasr⁴, Sravani Lokineni⁵, Christina Donath⁴, SARA KAHLOWN⁶, Damira Sereda¹, Binod Kc¹, Ilya Ivyanskiy¹, Bhavya Poudyal⁷, Arthur Weinstein⁸, Rosalind Ramsey-Goldman⁹, Michael Weisman¹⁰, Cynthia Aranow¹¹, Mariko Ishimori¹⁰, Kyriakos Kirou¹², Jihad Ben Gabr¹³, Sheetal Rayancha¹⁴, Nancy Olsen¹⁵, Fotios Koumpouras¹⁶, Judith Lin¹⁷, Stephen Faraone¹, Daniel Wallace¹⁸, Michael McDermott¹⁹ and Andras Perl²⁰, ¹SUNY Upstate Medical University, Syracuse, NY, ²Upstate Medical University, Syracuse, NY, ³Medical Affiliates of Cape Cod, Hyannis, MA, ⁴SUNY Upstate University Hospital, Syracuse, NY, ⁵Deaconess Hospital, Evansville, IN, ⁶Suny upstate medical university, Camillus, NY, ⁷SUNY Upstate Medical University, Cicero, NY, ⁸retired from clinical practice, volunteer academic faculty, Claremont, CA, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Cedars-Sinai Medical Center, LOS ANGELES, CA, ¹¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Hospital for Special Surgery, New York, NY, ¹³Division of Rheumatology & Clinical Immunology, SUNY Upstate Medical University, Syracuse, NY, ¹⁴SUNY Upstate Medical University, Jamesville, NY, ¹⁵Penn State University/Milton S Hershey, Hershey, PA, ¹⁶Yale School of Medicine, New Haven, CT, ¹⁷Ohio State University Wexner Medical Center, Columbus, OH, ¹⁸Cedars Sinai Medical Center, Studio City, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in 5 years. The major causes of death…
Abstract Number: 0634 • ACR Convergence 2025
Association of Lifestyle and Integrative Health Practices with Health-Related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
Sarah Lieber¹, Yongjay Kim², Lucy Masto³, Amaya Smole⁴, Neha Nagpal¹, Ranqing Lan¹, Michael Parides¹, Caroline Siegel¹, Lisa Mandl¹, Michael Lockshin⁵, Medha Barbhaiya¹ and Lisa Sammaritano¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Englewood Cliffs, NJ, ³Hospital for Special Surgery, San Francisco, CA, ⁴Hospital for Special Surgery, Brooklyn, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although available evidence supports the benefits of lifestyle interventions in SLE, the prevalence of lifestyle and integrative health behaviors and their association with health-related…
Abstract Number: 0616 • ACR Convergence 2025
Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
Juliana Silvatti¹, Livia Almeida Dutra², Larissa Araujo Duarte³, Andreza Salvio Lemos³, Helena Alessi⁴, Shaila Amorim Vieira², Gabriel D'Angelo Lacerda², LILIA ALVES MARIA ALVES MARIA⁴, Soniza Leon Alves³ and Cristiane Kayser⁴, ¹Universidade Federal de São Paulo, SAO PAULO, Sao Paulo, Brazil, ²Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Sao Paulo, Brazil, ³Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Universidade Federal de São Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently represent a diagnostic challenge due to its heterogeneous manifestations. Neurofilament light chain (NfL)…
Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Ali Ardekani¹, Alain Sanchez-Rodriguez², Mariana González-Treviño³, Jose Meade-Aguilar⁴, Maria O. Valenzuela-Almada⁵, Hannah Langenfeld¹, Larry J. Prokop⁴, Isabel Valenzuela Almada⁶, Gabriel Figueroa-Parra⁷, Nicolás Sánchez Domínguez⁸, Alejandro A. Rabinstein⁴, M. Hassan Murad⁴, Cynthia Crowson⁹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²ABC Medical Center, Ciudad de México, Federal District, Mexico, ³Vanderbilt University Medical Center, Nashville, ⁴Mayo Clinic, Rochester, ⁵Children’s National Medical Center, Washington D.C, ⁶Universidad Panamericana, Ciudad de México, Federal District, Mexico, ⁷Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁸Clínica Alemana de Santiago, Santiago, Chile, ⁹Mayo Clinic, Stewartvillle, MN
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 0363 • ACR Convergence 2025
Assessing Whole Health Needs in Systemic Lupus Erythematosus
Amanda Eudy¹, Megan Clowse², Dana Burshell³, Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Rebecca Sadun⁶, Ralph Snyderman⁷, Kai Sun⁶, Lisa Criscione-Schreiber³, Mithu Maheswaranathan³, Nathaniel Harris⁵, Jayanth Doss⁸ and Jennifer Rogers³, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, NC, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC
Background/Purpose: Care models that take a ‘Whole Health’ perspective by emphasizing personalized care focused on the individual’s values, needs, and goals, rather than solely on…
Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Elizabeth Sloan¹, Blake Baay², Lynnette Walters², Paola Sparagana², Kristina Ciaglia¹, Simrat Morris¹, Julie Fuller¹, Lorien Nassi¹, Tracey Wright¹ and Ayesha Zia³, ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²Scottish Rite for Children, Dallas, TX, ³UT Southwestern and Children's Medical Center, Dallas, TX
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].